These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 16227966

  • 1. Phase III randomized study of autologous lymphoma-derived idiotype specific vaccination plus GM-CSF in patients with follicular lymphoma in first complete remission.
    Clin Adv Hematol Oncol; 2003 Jan; 1(1):67. PubMed ID: 16227966
    [No Abstract] [Full Text] [Related]

  • 2. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma.
    Bendandi M, Gocke CD, Kobrin CB, Benko FA, Sternas LA, Pennington R, Watson TM, Reynolds CW, Gause BL, Duffey PL, Jaffe ES, Creekmore SP, Longo DL, Kwak LW.
    Nat Med; 1999 Oct; 5(10):1171-7. PubMed ID: 10502821
    [Abstract] [Full Text] [Related]

  • 3. Therapeutic lymphoma vaccines: importance of T-cell immunity.
    Neelapu SS, Lee ST, Qin H, Cha SC, Woo AF, Kwak LW.
    Expert Rev Vaccines; 2006 Jun; 5(3):381-94. PubMed ID: 16827622
    [Abstract] [Full Text] [Related]

  • 4. Cancer vaccine strategies get bigger and better.
    de Gruijl TD, Curiel DT.
    Nat Med; 1999 Oct; 5(10):1124-5. PubMed ID: 10502808
    [No Abstract] [Full Text] [Related]

  • 5. Translational development of vaccination strategies in follicular NHL.
    Sakamaki I, Qin H, Kwak LW.
    Best Pract Res Clin Haematol; 2011 Jun; 24(2):295-304. PubMed ID: 21658625
    [Abstract] [Full Text] [Related]

  • 6. Idiotype vaccination in follicular lymphoma: knocking on the doorway to cure.
    Longo DL.
    J Natl Cancer Inst; 2006 Sep 20; 98(18):1263-5. PubMed ID: 16985240
    [No Abstract] [Full Text] [Related]

  • 7. BiovaxID idiotype vaccination: active immunotherapy for follicular lymphoma.
    Flowers CR.
    Expert Rev Vaccines; 2007 Jun 20; 6(3):307-17. PubMed ID: 17542746
    [Abstract] [Full Text] [Related]

  • 8. Identifying patients with follicular lymphoma who are likely to benefit from an idiotype vaccine.
    Ansell SM, Suman VJ.
    J Clin Oncol; 2011 Jul 10; 29(20):2748-9. PubMed ID: 21632499
    [No Abstract] [Full Text] [Related]

  • 9. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma.
    Inogès S, Rodrìguez-Calvillo M, Zabalegui N, Lòpez-Dìaz de Cerio A, Villanueva H, Soria E, Suárez L, Rodríguez-Caballero A, Pastor F, García-Muñóz R, Panizo C, Pèrez-Calvo J, Melero I, Rocha E, Orfao A, Bendandi M, Grupo Español de Linfomas/Trasplante Autologo de Medula Oseo study group, Programa para el Estudio y Tratamiento de Hemopatias Malignas study group.
    J Natl Cancer Inst; 2006 Sep 20; 98(18):1292-301. PubMed ID: 16985248
    [Abstract] [Full Text] [Related]

  • 10. Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients.
    Hansson L, Abdalla AO, Moshfegh A, Choudhury A, Rabbani H, Nilsson B, Osterborg A, Mellstedt H.
    Clin Cancer Res; 2007 Mar 01; 13(5):1503-10. PubMed ID: 17332295
    [Abstract] [Full Text] [Related]

  • 11. Anti-idiotypic Immunotherapy in follicular lymphoma patients: results of a long follow-up study.
    Yáñez R, Barrios Y, Ruiz E, Cabrera R, Díaz-Espada F.
    J Immunother; 2008 Apr 01; 31(3):310-2. PubMed ID: 18317357
    [Abstract] [Full Text] [Related]

  • 12. Cloning of idiotype immunoglobulin genes in B cell lymphomas by anchored PCR and production of individual recombinant idiotype vaccines in Escherichia coli.
    Bertinetti C, Simon F, Zirlik K, Heining-Mikesch K, Pfeifer D, Osterroth F, Rosenthal FM, Veelken H.
    Eur J Haematol; 2006 Nov 01; 77(5):395-402. PubMed ID: 16879605
    [Abstract] [Full Text] [Related]

  • 13. Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma.
    Freedman A, Neelapu SS, Nichols C, Robertson MJ, Djulbegovic B, Winter JN, Bender JF, Gold DP, Ghalie RG, Stewart ME, Esquibel V, Hamlin P.
    J Clin Oncol; 2009 Jun 20; 27(18):3036-43. PubMed ID: 19414675
    [Abstract] [Full Text] [Related]

  • 14. Idiotype vaccination as consolidation therapy: time for integration into standard of care for follicular lymphoma?
    Schuster SJ, Neelapu SS, Santos CF, Popa-McKiver MA, McCord AM, Kwak LW.
    J Clin Oncol; 2011 Dec 20; 29(36):4845-6. PubMed ID: 22042953
    [No Abstract] [Full Text] [Related]

  • 15. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma.
    Schuster SJ, Neelapu SS, Gause BL, Janik JE, Muggia FM, Gockerman JP, Winter JN, Flowers CR, Nikcevich DA, Sotomayor EM, McGaughey DS, Jaffe ES, Chong EA, Reynolds CW, Berry DA, Santos CF, Popa MA, McCord AM, Kwak LW.
    J Clin Oncol; 2011 Jul 10; 29(20):2787-94. PubMed ID: 21632504
    [Abstract] [Full Text] [Related]

  • 16. BiovaxID, a personalized therapeutic vaccine against B-cell lymphomas.
    Reinis M.
    Curr Opin Mol Ther; 2008 Oct 10; 10(5):526-34. PubMed ID: 18830928
    [Abstract] [Full Text] [Related]

  • 17. Clinical results of the ID-KLH vaccination with local GM-CSF in patients with follicular lymphomas (published in Nature Med 1999; 5: 1171-1177) summary of the lecture by L. W. Kwak.
    Schumacher K.
    J Cancer Res Clin Oncol; 2001 Oct 10; 127 Suppl 2():R10-3. PubMed ID: 11768618
    [No Abstract] [Full Text] [Related]

  • 18. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease.
    Dessureault S, Noyes D, Lee D, Dunn M, Janssen W, Cantor A, Sotomayor E, Messina J, Antonia SJ.
    Ann Surg Oncol; 2007 Feb 10; 14(2):869-84. PubMed ID: 17103257
    [Abstract] [Full Text] [Related]

  • 19. Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: safety and immunogenicity in a phase I clinical study.
    McCormick AA, Reddy S, Reinl SJ, Cameron TI, Czerwinkski DK, Vojdani F, Hanley KM, Garger SJ, White EL, Novak J, Barrett J, Holtz RB, Tusé D, Levy R.
    Proc Natl Acad Sci U S A; 2008 Jul 22; 105(29):10131-6. PubMed ID: 18645180
    [Abstract] [Full Text] [Related]

  • 20. Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression.
    Bertinetti C, Zirlik K, Heining-Mikesch K, Ihorst G, Dierbach H, Waller CF, Veelken H.
    Cancer Res; 2006 Apr 15; 66(8):4496-502. PubMed ID: 16618777
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.